Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LNTH - Lantheus Holdings, Inc.

IEX Last Trade
91.84
-0.020   -0.022%

Share volume: 10,948
Last Updated: Fri 27 Dec 2024 08:29:51 PM CET

PREVIOUS CLOSE
CHG
CHG%
$91.86
-0.02
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.46%
1 Month
3.30%
3 Months
-13.14%
6 Months
14.68%
1 Year
51.60%
2 Year
89.92%
Key data
Stock price
$91.84
P/E Ratio 
17.25
DAY RANGE
$91.21 - $92.95
EPS 
$6.06
52 WEEK RANGE
$52.79 - $126.89
52 WEEK CHANGE
$50.40
MARKET CAP 
7.392 B
YIELD 
N/A
SHARES OUTSTANDING 
69.431 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
0.86
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,006,714
AVERAGE 30 VOLUME 
$883,722
Company detail
CEO: Mary A. Heino
Region: US
Website: lantheus.com
Employees: 700
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates disease burden of prostate cancer by quantifying the hotspots on bone scans.

Recent news